Finance

Lists
Q2 2026 earnings • released • EPS miss -2.56%
See results
COAG:NASDAQ
Hemab Therapeutics Holdings Inc
$54.94
+1.84%
(+0.99) 1D
$54.94
0.00% (0.00)
After hours
Closed: Aug 14, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for COAG...
Open
$53.76
High
$55.42
Low
$50.59
Mkt. cap
2.57B
Avg. vol.
398.55K
Volume
101.17K
52-wk high
$55.42
52-wk low
$23.00
No. of employees
72
Open
$53.76
High
$55.42
Low
$50.59
Mkt. cap
2.57B
Avg. vol.
398.55K
Volume
101.17K
52-wk high
$55.42
52-wk low
$23.00
No. of employees
72
News stories
From web sources and news partners
About Hemab Therapeutics Holdings Inc
CEO-
Employees72
Founded2020
Headquarters-
SectorBiotechnology
Websitehemab.com
Analyst ratings
Based on 5 analysts giving stock ratings to COAG in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for COAG in the last 3 months.
Highest
Current $54.94
$64.00 (+16.49%)
Average
$53.40 (-2.80%)
Lowest
$46.00 (-16.27%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Nierengarten
Wedbush
Buy
Maintained
$64.00
+16.5%
08/12/2026
Emily Bodnar
H.C. Wainwright
Buy
Reiterated
$60.00
+9.2%
08/11/2026
Richard Law CFA
Goldman Sachs
Buy
Maintained
$46.00
-16.3%
07/13/2026
Maury Raycroft
Jefferies
Buy
Maintained
$47.00
-14.5%
07/13/2026
Cory Kasimov
Evercore ISI
Buy
Initiated
$50.00
-9%
05/26/2026
Last report
Aug 11, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.80 / -$0.78
-2.56%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Mar 2026
Revenue
-
-
Cost of goods sold
-
-
Cost of revenue
-
-
Research and development expenses
14.10M
19.46M
Total research and development expenses
-
-
Selling, general, and admin expenses
2.46M
4.15M
Operating expense
16.56M
23.61M
Total operating expenses
16.56M
23.61M
Operating income
-16.56M
-23.61M
Other non operating income
591.00K
-282.00K
EBT including unusual items
-15.50M
-22.68M
EBT excluding unusual items
-15.50M
-22.68M
Income tax expense
-190.00K
12.00K
Effective tax rate
1.23%
-0.05%
Other operating expenses
-
-
Net income
-15.31M
-22.69M
Net profit margin
-
-
Earnings per share
-
-
Interest and investment income
473.00K
1.22M
Interest expense
-
-
Net interest expenses
473.00K
1.22M
Depreciation and amortization charges
-
-
EBITDA
-16.48M
-23.54M
Gain or loss from assets sale
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps